- $368.55m
- $326.71m
- $79.18m
Brief: Simulations Plus Enters New Collaboration To Enhance Machine Learning Models For Ionization Constants
Simulations Plus Inc reports results for the quarter ended in May - Earnings Summary
Simulations Plus rises on higher Q3 revenue and profit
Brief: Simulations Plus Reports Q3 EPS Of $0.20
Simulations Plus Inc expected to post earnings of 18 cents a share - Earnings Preview
Brief: Simulations Plus Collaborates With Pharmaceutical Firm
Brief: Simulations Plus Inc - U.S. FDA Renews Annual DILIsym Software Licenses For 2022
Brief: Simulations Plus Successfully Delivers FDA-Funded Project
Brief: Simulations Plus Announces Funded Collaboration With Pharmaceutical Firm
Simulations Plus Inc reports results for the quarter ended in February - Earnings Summary
Brief: Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
Simulations Plus Inc expected to post earnings of 14 cents a share - Earnings Preview
Brief: Simulations Plus Gets $1.7 Million Grant For BIOLOGXsym Macromolecule Safety Software
Brief: Simulations Plus Releases Membraneplus 3.0
Brief: Simulations Plus Partners With Large Pharmaceutical Company To Drive Advancements To Gastroplus Mechanistic Oral Absorption Model
Brief: Simulations Plus Enters New Collaboration With Leading Animal Health Company
Brief: Simulations Plus Reports First Quarter Fiscal 2022 Financial Results
Simulations Plus Inc reports results for the quarter ended in November - Earnings Summary
Simulations Plus Inc expected to post earnings of 9 cents a share - Earnings Preview